I-Mab (NASDAQ:NBP) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• I-Mab (NASDAQ:NBP) was downgraded by Wall Street Zen from a "hold" to a "sell," marking a negative analyst move on the stock.
• Analyst views are mixed: HC Wainwright still rates the stock a "buy" with a $9 target while Weiss Ratings and Wall Street Zen rate it "sell," leaving a MarketBeat consensus of "Hold" and an average target of $9.
• The shares trade near $2.36 with a 52-week range of $0.63–$6.79, a market cap of about $272 million, recent quarterly EPS of ($0.30), and roughly 38% institutional ownership.

I-Mab (NASDAQ:NBP - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of I-Mab in a research note on Wednesday. Weiss Ratings assumed coverage on shares of I-Mab in a research note on Thursday, February 5th. They set a "sell (d-)" rating for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $9.00.

I-Mab Price Performance

I-Mab stock opened at $2.36 on Friday. I-Mab has a fifty-two week low of $0.63 and a fifty-two week high of $6.79. The stock has a market cap of $272.08 million, a P/E ratio of -6.56 and a beta of 1.74. The firm has a 50-day moving average price of $2.97.

I-Mab (NASDAQ:NBP - Get Free Report) last posted its earnings results on Tuesday, April 7th. The company reported ($0.30) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,715 shares of the company's stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors and hedge funds.

More I-Mab News

Here are the key news stories impacting I-Mab this week:

• Positive Sentiment: External note highlights drug catalyst — A recent industry writeup flags Givastomig as a potential major re‑rating catalyst based on strong Phase 1b data (high response rate, extended PFS and manageable safety); upcoming 2026 Phase 1b readouts and any accelerated‑approval talk could provide upside for I‑Mab’s lead program. NovaBridge's Givastomig Could Drive A Major Re-Rating
• Neutral Sentiment: HC Wainwright retains a "Buy" rating and a $9.00 target — despite sweeping estimate cuts, the firm kept a bullish rating and a high target, which can provide some analyst‑support to the share price and suggests belief in longer‑term pipeline value. (No direct link available.)
• Negative Sentiment: Broad EPS downgrades from HC Wainwright — the analyst cut Q1–Q4 2026 and multiple FY2026–FY2030 EPS estimates materially (e.g., FY2026 to ($0.56) from ($0.35), FY2027 to ($1.00) from ($0.69), FY2030 to ($0.71) from $0.14). These downward revisions highlight expected higher burn, delayed revenue/catalysts or larger R&D spend, and are pressuring the stock lower today.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.